Fingolimod (FTY720) in severe hepatic impairment: Pharmacokinetics and relationship to markers of liver function

Journal of Clinical Pharmacology

Volumn 46, Issue 2, 2006, Pages 149-156

  Kovarik, John M ^a,b   Schmouder, Robert L ^a,b   Hartmann, Stefan ^a,b   Riviere, Gilles Jacques ^a,b   Picard, Franck ^a,b   Voss, Brigitta ^a,b   Weiss, Markus ^a,b   Wagner, Frank ^c   Schmidt, Hartmut H J ^d,e  

^a NOVARTIS PHARMA AG   (Switzerland)

^b NOVARTIS PHARMA K K   (Japan)

^c Universitätsklinikum Charité ^*  (Germany)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Dose adjustment; Fingolimod; Hepatic impairment; Immunosuppression

Indexed keywords

ALBUMIN; ASPARTIC ACID; BILIRUBIN; FINGOLIMOD; FOLIC ACID; FUROSEMIDE; IMMUNOMODULATING AGENT; LACTULOSE; PANTOPRAZOLE; PHYTOMENADIONE; SPIRONOLACTONE; TORASEMIDE; XIPAMIDE;

ADULT; ALCOHOLISM; ARTICLE; ASCITES; ATRIOVENTRICULAR BLOCK; BILIRUBIN BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DOSE TIME EFFECT RELATION; DRUG CAPSULE; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PROTEIN BINDING; FEMALE; HEART RATE; HEPATITIS C; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; LIQUID CHROMATOGRAPHY; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FUNCTION; LYMPHOCYTE COUNT; MALE; MULTIPLE SCLEROSIS; OPEN STUDY; PROTHROMBIN TIME; SINGLE DRUG DOSE; TANDEM MASS SPECTROMETRY; TREATMENT OUTCOME;

ADULT; AREA UNDER CURVE; BILIRUBIN; BIOLOGICAL MARKERS; FEMALE; HALF-LIFE; HEART RATE; HUMANS; IMMUNOLOGIC FACTORS; LIVER DISEASES, ALCOHOLIC; LIVER FUNCTION TESTS; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; PROPYLENE GLYCOLS; PROTEIN BINDING; PROTHROMBIN TIME; SPHINGOSINE;

EID: 31344464646     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270005283464     Document Type: Article

References (8)

1. Brinkmann V, Cyster JG, Hla T. FTY720: sphingosine 1-phosphate receptor-1 in the control of lymphocyte egress and endothelial barrier function. Am J Transplant. 2004;4:1019-1025.
2. Kovarik JM, Schmouder R, Barilla D, Wang Y, Kraus G. Single-dose FTY720 pharmacokinetics, food effect, and pharmacological responses in healthy subjects. Br J Clin Pharmacol. 2004;57:586-591.
3. Kovarik JM, Schmouder RL, Slade A. Overview of FTY720 clinical pharmacology and pharmacokinetics. Ther Drug Monit. 2004;26:585-587.
4. Kovarik JM, Schmouder RL, Serra D, et al. FTY720 pharmacokinetics in mild to moderate hepatic impairment. J Clin Pharmacol. 2005;45:446-452.
5. Pugh RNH, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973;60:646-649.
6. Kovarik JM, Schmidli H, Meno-Tetang G, Slade A, Picard F, Schmouder RL. Insights into FTY720 use in transplantation from a human exposure-lymphocyte mechanistic model based on clinical data [abstract]. Am J Transplant. 2005;5(suppl 11):190.
7. Schmouder R, DiMarco J, Serra D, et al. FTY720 multiple dosing does not result in progressive reduction of heart rate [abstract]. Am J Transplant. 2005;5(suppl 11):398.
8. Slade A, Kovarik J, Hunt T, Schmouder R. FTY720 heart rate reduction: doses from 5 mg to 40 mg do not result in any greater heart rate effect [abstract]. Am J Transplant. 2005;5(suppl 11):398.